Back to Cell Types

Panc 02.03Homo sapiens (Human)Cancer cell line

Also known as: Panc0203, PANC0203, PANC203, Panc203, PANC 203, Panc2_03, Panc2.03, Panc 2.03, Panc02.03, Panc_02_03, PANC-02-03

🤖 AI SummaryBased on 9 publications

Quick Overview

Pancreatic cancer cell line with known chromosomal abnormalities and metabolic subtypes.

Detailed Summary

Panc 02.03 is a pancreatic cancer cell line derived from human tissue, characterized by significant chromosomal abnormalities and metabolic heterogeneity. It has been used in studies to identify distinct metabolic subtypes, including glycolytic and lipogenic profiles, which correlate with different therapeutic responses. The cell line exhibits complex chromosomal rearrangements, particularly in regions such as 18q, and has been utilized in research to understand the molecular mechanisms underlying pancreatic cancer progression and drug sensitivity. Its metabolic characteristics make it a valuable model for studying the impact of metabolic inhibitors on cancer cell growth.

Research Applications

Chromosomal abnormality analysisMetabolic subtype identificationDrug sensitivity profilingGene fusion detection

Key Characteristics

Complex chromosomal rearrangementsMetabolic heterogeneityKnown 18q abnormalitiesUsed in metabolic inhibitor studies

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1633
Species	Homo sapiens (Human)
Tissue Source	Pancreas[UBERON:UBERON_0001264]

Donor Information

Age	70
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000042_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Gln (c.743G>A)	Unspecified	Somatic mutation acquired during proliferation	PubMed=20575032
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D13S317

12

D16S539

11

D18S51

14

D19S433

13,16

D21S11

28,31

D2S1338

19,20

D3S1358

14

D5S818

12,13

D7S820

9,10

D8S1179

11,12

FGA

20,21

Penta D

9

Penta E

5,7

TH01

6

TPOX

9,12

vWA

17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.

Biankin A.V., Wu J.-M., Daly R.J.

Mol. Cell. Proteomics 15:2671-2685(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Mendell J.T.

Cancer Biol. Ther. 8:2013-2024(2009).

Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.

Ried T., Schrock E., Perlman E.J., Jaffee E.M.

Cytogenet. Genome Res. 118:148-156(2007).

Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.

Thomas M., Greten T.F., Hruban R.H., Yeo C.J., Griffin C.A.

Cancer J. Sci. Am. 4:194-203(1998).

Web Resources

dpsc.ccbr.utoronto.ca tcpaportal.org